We are live on
!
Find out more
MACM
March Altus Capital Management Portfolio holdings
AUM
$16M
1-Year Est. Return
18.92%
This Fund
S&P 500
This Quarter
Est. Return
+7.76%
1 Year Est. Return
+18.92%
3 Year Est. Return
+155.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$311M
AUM Growth
-$18.7M
(-5.7%)
Cap. Flow
-$28.5M
Cap. Flow
% of AUM
-9.16%
Top 10 Holdings %
Top 10 Hldgs %
51.43%
Holding
37
New
9
Increased
4
Reduced
13
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
United Therapeutics
UTHR
|
+$17.1M |
| 2 |
Insulet
PODD
|
+$12M |
| 3 |
Biogen
BIIB
|
+$11.7M |
| 4 |
Incyte
INCY
|
+$11.3M |
| 5 |
Zoetis
ZTS
|
+$11M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aon
AON
|
+$12.3M |
| 2 |
Baxter International
BAX
|
+$12.1M |
| 3 |
Humana
HUM
|
+$11.6M |
| 4 |
eHealth
EHTH
|
+$11.3M |
| 5 |
Perrigo
PRGO
|
+$11.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.92% |
| 2 | Materials | 5.92% |
| 3 | Industrials | 4.21% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
DexCom
DXCM
$28.8B
| $28.9M | 9.28% |
2,795,340
-544,012
| -16% | -$5.62M |
|
2
Alkermes
ALKS
$8.39B
| $20.4M | 6.55% |
462,853
| – | – |
|
|
MON
3
DELISTED
Monsanto Co
MON
| $18.4M | 5.92% |
162,131
-36,857
| -19% | -$4.1M |
|
4
Eli Lilly
LLY
$1.03T
| $15.8M | 5.07% |
268,087
+41,249
| +18% | +$2.3M |
|
|
5
United Therapeutics
UTHR
$26.2B
| $15.7M | 5.03% |
+166,725
| New | +$17.1M |
|
|
ATHN
6
DELISTED
Athenahealth, Inc.
ATHN
| $13.1M | 4.21% |
81,916
+15,690
| +24% | +$2.58M |
|
|
7
Insulet
PODD
$11.5B
| $12.8M | 4.12% |
+270,717
| New | +$12M |
|
|
AGN
8
DELISTED
Allergan Inc
AGN
| $12M | 3.85% |
96,627
-9,018
| -9% | -$1.1M |
|
|
MNK
9
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $11.5M | 3.7% |
181,966
-39,119
| -18% | -$2.47M |
|
|
ZLTQ
10
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
| $11.5M | 3.69% |
586,065
-170,440
| -23% | -$3.32M |
|
|
11
Biogen
BIIB
$30.7B
| $11.3M | 3.63% |
+36,976
| New | +$11.7M |
|
|
ALXN
12
DELISTED
Alexion Pharmaceuticals
ALXN
| $11.3M | 3.62% |
74,111
-17,300
| -19% | -$2.75M |
|
|
13
Zoetis
ZTS
$31.9B
| $10.4M | 3.35% |
+360,761
| New | +$11M |
|
14
Universal Health Services
UHS
$9.88B
| $10.2M | 3.26% |
123,759
-20,747
| -14% | -$1.67M |
|
15
HCA Healthcare
HCA
$85.7B
| $10.1M | 3.26% |
193,226
-174,164
| -47% | -$8.67M |
|
|
16
Incyte
INCY
$24.9B
| $9.75M | 3.13% |
+182,192
| New | +$11.3M |
|
|
CYBX
17
DELISTED
CYBERONICS INC
CYBX
| $9.31M | 2.99% |
142,636
-24,252
| -15% | -$1.63M |
|
18
West Pharmaceutical
WST
$23.9B
| $9.2M | 2.95% |
208,801
-128,360
| -38% | -$6.04M |
|
|
LMNX
19
DELISTED
Luminex Corp
LMNX
| $9.09M | 2.92% |
+501,923
| New | +$9.4M |
|
20
Tandem Diabetes Care
TNDM
$1.3B
| $8.13M | 2.61% |
36,826
-5,976
| -14% | -$1.52M |
|
|
UNIS
21
DELISTED
Unilife Corporation
UNIS
| $7.57M | 2.43% |
185,919
+18,176
| +11% | +$821K |
|
|
ENZY
22
DELISTED
Enzymotec Ltd
ENZY
| $7.22M | 2.32% |
327,962
+125,000
| +62% | +$3.31M |
|
23
Encompass Health
EHC
$11B
| $6.92M | 2.22% |
242,147
-155,646
| -39% | -$4.05M |
|
24
Accuray
ARAY
$33.9M
| $6.59M | 2.12% |
686,569
| – | – |
|
|
NUVA
25
DELISTED
NuVasive, Inc.
NUVA
| $6.29M | 2.02% |
+163,675
| New | +$6.01M |
|
Similar funds
IC
PA
GMIM
JHWCP
SMPIAI
NCMG
CAD
GPI
March Altus Capital Management's Q1 2014 Portfolio in Review
As of Q1 2014, March Altus Capital Management held 37 positions worth $311M, down 5.7% from $330M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
March Altus Capital Management withdrew a net $28.5M in Q1 2014, closing 9 positions and reducing 13 holdings. Its most notable exit was Aon, an estimated $12.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 75% a quarter earlier, followed by Materials and Industrials.
Against the trend, March Altus Capital Management opened a new position in United Therapeutics worth $15.7M.
- March Altus Capital Management's largest Q1 2014 buy was United Therapeutics: 166,725 shares worth $15.7M.
- March Altus Capital Management added most to Enzymotec Ltd in Q1 2014, an estimated $3.31M increase.
- March Altus Capital Management's biggest Q1 2014 reduction was HCA Healthcare, cutting an estimated $8.67M.
- March Altus Capital Management fully exited Aon in Q1 2014, selling an estimated $12.3M.
- March Altus Capital Management's ten largest holdings make up 51% of its $311M portfolio in Q1 2014.
- March Altus Capital Management opened 9 new positions and closed 9 in Q1 2014.
- March Altus Capital Management's portfolio value fell 5.7% quarter-over-quarter to $311M.
Based on March Altus Capital Management's 13F filing for Q1 2014, filed 15 May 2014.